ATE470857T1 - Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität - Google Patents

Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität

Info

Publication number
ATE470857T1
ATE470857T1 AT06749210T AT06749210T ATE470857T1 AT E470857 T1 ATE470857 T1 AT E470857T1 AT 06749210 T AT06749210 T AT 06749210T AT 06749210 T AT06749210 T AT 06749210T AT E470857 T1 ATE470857 T1 AT E470857T1
Authority
AT
Austria
Prior art keywords
clostridial toxin
clostridial
toxinactivity
lipophilic
dye
Prior art date
Application number
AT06749210T
Other languages
English (en)
Inventor
Ester Fernandez-Salas
Lance Steward
Kei Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE470857T1 publication Critical patent/ATE470857T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06749210T 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität ATE470857T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66894205P 2005-04-05 2005-04-05
PCT/US2006/012426 WO2006107921A2 (en) 2005-04-05 2006-04-04 Lipophilic dye-based fret assays for clostridial toxin activity

Publications (1)

Publication Number Publication Date
ATE470857T1 true ATE470857T1 (de) 2010-06-15

Family

ID=36975328

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06749210T ATE470857T1 (de) 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
AT10164461T ATE552500T1 (de) 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT10164461T ATE552500T1 (de) 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität

Country Status (10)

Country Link
US (2) US8124357B2 (de)
EP (2) EP2293064B1 (de)
AT (2) ATE470857T1 (de)
AU (1) AU2006231470B2 (de)
CA (1) CA2604039C (de)
DE (1) DE602006014812D1 (de)
DK (1) DK1869459T3 (de)
ES (1) ES2345506T3 (de)
PT (1) PT1869459E (de)
WO (1) WO2006107921A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
WO2005082096A2 (en) * 2004-02-24 2005-09-09 Allergan, Inc. Botulinum toxin screening assays
WO2006107921A2 (en) * 2005-04-05 2006-10-12 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity
ATE555387T1 (de) * 2005-10-12 2012-05-15 Allergan Inc Tests der molekularen oder subzellulären nähe unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
US7713927B2 (en) 2007-01-16 2010-05-11 The Regents Of The University Of California Antimicrobial peptides
CA2715033C (en) 2008-03-14 2014-11-25 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
MX2011009606A (es) * 2009-03-13 2011-09-28 Allergan Inc Ensayo de actividad de endopeptidasa redirigida basados en inmunoensayos.
SG174350A1 (en) 2009-03-13 2011-10-28 Allergan Inc Cells useful for immuno-based botulinum toxin serotype a activity assays
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
DK2488868T3 (en) * 2009-10-16 2016-05-09 Biomadison Inc Resonansenergioverføringsassay with synaptobrevinsubstratdel
US10246492B2 (en) 2009-10-16 2019-04-02 Biomadison, Inc. Botulinum assay with synaptobrevin substrate moiety
EP2580345A4 (de) * 2010-06-11 2014-06-18 Synaptic Res Llc Verfahren zur anzeige einer n-end-regel-proteaseaktivität und verwendungen davon
SG11201403010TA (en) * 2011-12-09 2014-07-30 Pasteur Institut Multiplex immuno screening assay
US10451621B2 (en) 2011-12-31 2019-10-22 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
US8778623B2 (en) * 2012-09-14 2014-07-15 Wisconsin Alumni Research Foundation Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin
US8962340B2 (en) 2012-12-03 2015-02-24 Src, Inc. Real-time assay for the detection of botulinum toxin
DE102013226537B4 (de) 2013-12-18 2022-12-29 TRUMPF Hüttinger GmbH + Co. KG Leistungsversorgungssystem mit mehreren Verstärkerpfaden sowie Verfahren zur Anregung eines Plasmas
DE102013226511B4 (de) 2013-12-18 2016-12-15 TRUMPF Hüttinger GmbH + Co. KG Leistungsversorgungssystem und Verfahren zur Erzeugung einer Leistung
CA2954504A1 (en) 2014-07-07 2016-01-14 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
US9788776B1 (en) 2014-09-22 2017-10-17 Verily Life Sciences Llc Protein M-based in vivo diagnostic system and detection method
US9927442B1 (en) 2014-10-31 2018-03-27 Verily Life Sciences Llc Biosensor for in vitro detection system and method of use
US10900955B2 (en) 2014-12-19 2021-01-26 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of BoNT/E in cells
KR20240023684A (ko) 2016-09-13 2024-02-22 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019126502A1 (en) 2017-12-20 2019-06-27 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
TW202113072A (zh) * 2019-06-07 2021-04-01 美商辛那皮克研究有限責任公司 基因工程化細胞
JP2022544265A (ja) * 2019-08-13 2022-10-17 イプセン バイオファーム リミテッド クロストリジウム神経毒に対して高度に感受性の細胞
CN110882276B (zh) * 2019-11-23 2021-07-06 博雅干细胞科技有限公司 细胞治疗组合物及治疗血管病变的方法
CN110840914B (zh) * 2019-11-23 2021-07-06 博雅干细胞科技有限公司 细胞治疗剂用于缓解或改善血管病变的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
FR2809733B1 (fr) * 2000-06-02 2004-04-30 Inst Nat Sante Rech Med Substrat peptidique reconnu par la toxine botulique de type bont/b et son utilisation pour doser et/ou detecter ladite toxine ou des inhibiteurs correspondants
ATE378596T1 (de) * 2000-09-25 2007-11-15 U S Medical Res Inst Of Infect Hoch-durchsatz assays für proteolytische aktivitäten von clostridium neurotoxinen
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) * 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20060063221A1 (en) * 2004-09-21 2006-03-23 Williams Dudley J Lanthanide-based substrates and methods for determining clostridial toxin activity
WO2004020748A1 (en) 2002-08-28 2004-03-11 Btb Wallercode Sdn Bhd Rainwater collection, storage and supply system
WO2004029567A1 (en) 2002-09-26 2004-04-08 Rensselaer Polytechnic Institute Analytical instruments for monitoring photopolymerization
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
AU2003272800A1 (en) 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP2502930B1 (de) * 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Verfahren und zusammensetzungen zum nachweis von botulinum-neurotoxin
CA2565678C (fr) 2004-05-05 2013-07-09 Pharmaleads Substrats peptidiques reconnus par la toxine botulique de type a, bont/a et leurs utilisations
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
WO2006107921A2 (en) * 2005-04-05 2006-10-12 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity

Also Published As

Publication number Publication date
CA2604039A1 (en) 2006-10-12
US20120231538A1 (en) 2012-09-13
EP1869459B1 (de) 2010-06-09
EP2293064A1 (de) 2011-03-09
US8124357B2 (en) 2012-02-28
EP2293064B1 (de) 2012-04-04
US8535941B2 (en) 2013-09-17
PT1869459E (pt) 2010-08-10
ES2345506T3 (es) 2010-09-24
DE602006014812D1 (de) 2010-07-22
WO2006107921A3 (en) 2007-01-18
DK1869459T3 (da) 2010-09-27
AU2006231470A1 (en) 2006-10-12
CA2604039C (en) 2014-09-16
AU2006231470B2 (en) 2011-12-01
EP1869459A2 (de) 2007-12-26
WO2006107921A2 (en) 2006-10-12
US20080160561A1 (en) 2008-07-03
ATE552500T1 (de) 2012-04-15

Similar Documents

Publication Publication Date Title
ATE552500T1 (de) Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
NO20051049D0 (no) Celle-baserte fluorescens-resonans energi overforings (FRET)-analyser for Clostridietoksiner
DK1920248T3 (da) Clostridialt-toksin-aktivitetsassays
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
WO2004041061A3 (en) Substrates, devices, and methods for cellular assays
DE602006018477D1 (de) Dna und antikörpern sowie verwendungen davon
ATE527383T1 (de) Multiplex-nukleinsäurenachweis
WO2007103859A3 (en) Methods, products, and kits for identifying an analyte in a sample
WO2006071247A3 (en) Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots
AU4701200A (en) A method of detecting an analyte using semiconductor nanocrystals
WO2006121799A3 (en) Liquid crystal based analyte detection
WO2007008276A3 (en) Turnover probes and use thereof for nucleic acid detection
WO2005047863A3 (en) Substrates, devices, and methods for cellular assays
WO2008066584A3 (en) Rapid analyte measurement assay
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
AU2003224447A1 (en) Device and method to simultaneously detect different antibodies and antigens in clinical alimentary and environmental samples
WO2006044747A3 (en) P27 ubiquitination assay and methods of use
NO20052553L (no) Cobalaminanalyse.
WO2005094441A3 (en) Split enzyme linked immunosorbent and nucleic acid assays
ATE533053T1 (de) Nicht-elispot-test
DE602004027085D1 (de) M für leberkrebs sowie heilmittel gegen krebs
WO2007133496A3 (en) Development of a novel assay for mgmt (methyl guanine transferase)
WO2009017234A1 (ja) γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法
ATE365324T1 (de) Nachweis durch serrs in mikrofluidischer umgebung
DE60331686D1 (de) Mikroarray-vorrichtungen mit steuerbarem reaktionsvolumen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1869459

Country of ref document: EP